BrightGene Bio-medical Technology(SH:688166) Soochow Securities·2025-08-10 14:17Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights the promising opportunities in the domestic oral weight-loss drug market, particularly recommending companies such as Borui Pharmaceutical and Gilead Sciences as key players [1][2] - The GLP-1 drug market is expected to see significant growth, with projections indicating a market size exceeding $150 billion by 2030, driven by increasing demand and new product approvals [6][12] - The report emphasizes the strong performance of innovative drugs, particularly GLP-1 and PD-1/VEGF dual antibodies, and suggests a focus on companies like Borui Pharmaceutical, Gilead Sciences, and others for investment [2][12] Summary by Sections Industry Performance - The A-share pharmaceutical index has shown a year-to-date increase of 21.3%, while the Hang Seng Biotechnology Index has surged by 87.2% [6][11] - Recent stock performance indicates a mixed trend, with notable gains in companies like Nanmo Biotechnology (+42%) and Haichen Pharmaceutical (+41%), while others like Nanxin Pharmaceutical (-19%) and Qizheng Tibetan Medicine (-16%) faced declines [11] Sub-industry Recommendations - The report ranks preferred sub-industries as follows: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [2][12] - Specific stock recommendations include: - From the GLP-1 perspective: Borui Pharmaceutical, Gilead Sciences, and others [2][12] - From the PD-1/VEGF dual antibody perspective: Kangfang Biotech, Shenzhou Cell, and others [2][12] - From a low valuation perspective: Zoli Pharmaceutical, Dong'e Ejiao, and others [2][12] Market Dynamics - The report notes that the GLP-1 drug market is significantly underestimated, with companies like Borui Pharmaceutical and Gilead Sciences expected to emerge as major players with potential market capitalizations in the hundreds of billions [6][12] - The report also discusses the competitive landscape, highlighting the rapid growth of drugs like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy, which have seen substantial sales increases [17][22] Financial Performance - Novo Nordisk reported a revenue of approximately $22.9 billion for the first half of 2025, reflecting an 18% year-on-year growth, driven by strong sales of its GLP-1 products [17][22] - Eli Lilly's revenue for the same period reached $28.3 billion, marking a 41% increase, with Mounjaro and Zepbound leading the sales growth [22][23]